Neumora Therapeutics NMRA
NASDAQ NMRA
$0.47 +0.01 (+1.37%)
At close: Nov 11, 2026 · 4:00 PM EST

Neumora Therapeutics (NMRA) Amortization of Deferred Charges (2025 - 2026)

Updated

Analysis

Neumora Therapeutics (NMRA) Amortization of Deferred Charges (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Neumora Therapeutics 88.31 Mn -529.65 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 394,000.00
Mar 31, 2026 418,000.00
Dec 31, 2025 201,000.00
Sep 30, 2025 213,000.00
Jun 30, 2025 303,000.00
API Access

Neumora Therapeutics Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=NMRA&period=max&api_key=YOUR_API_KEY